Inability to target the enhanced pre-mRNA splicing of metabolic genes in MYC-driven cancer cells by pharmacological inhibition of JMJD6 is another limitation, due to lack of selective and potent JMJD6 inhibitors. The gene discussed is MYC; the disease is cancer.